This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Currently, most patients diagnosed with progressive multifocal leukoencephalopathy (PML) are infected with HIV; highly active antiretroviral therapy (HAART) has prolonged the median survival of these patients from 3 months to 1 year.1 Despite encouraging initial case reports, other therapies, including cytosine arabinoside and alpha INF, have been disappointing for both HIV and non-HIV patients with PML.2–4 In addition to the lack of convincing evidence that these treatments alter the natural course of PML, there are concerns of toxicity in patients with low blood counts. Because a plausible biologic basis exists for a role for recombinant interleukin-2 (rIL-2) in the reconstitution of impaired antiviral immune functions, this immunotherapy was administered previously in a patient with PML with apparent success.5 Based on this report, we chose rIL-2 as initial therapy for a patient with myelodysplasia who developed PML.
Case report.
A 58-year-old woman with a 20-year history of myelodysplastic syndrome presented in March 2000 with dysarthria and right hand clumsiness, which developed …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Topics Discussed
Alert Me
Recommended articles
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy
Reactivation of JC virus and development of PML in patients with multiple sclerosis
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
AIDS-related focal brain lesions in the era of highly active antiretroviral therapy